Table 1.

Characteristics of 103 advanced biliary tract cancer patients treated with gemcitabine and oxaliplatin (GEMOX) with or without erlotinib

	Study population
	GEMOX (n = 54)	GEMOX plus erlotinib (n = 49)
Age, years
Median	62 (45–75)	59 (39–75)
Sex
Male	35 (64.8 %)	33 (67.3 %)
Female	19 (35.2 %)	16 (32.7 %)
Primary site
Cholangiocarcinoma	38 (70.4 %)	38 (77.6 %)
Gallbladder (GB)	16 (29.6 %)	11 (22.4 %)
Differentiation
Well/Moderate	33 (61.1 %)	26 (53.1 %)
Poorly	21 (38.9 %)	23 (46.9 %)
Disease status
Recurrent	4 (7.4 %)	18 (36.7 %)
Primarily metastatic	50 (92.6 %)	31 (63.3 %)
Liver only metastasis
Yes	10 (18.5 %)	8 (16.3 %)
No	44 (81.5 %)	41 (83.7 %)
Number of metastatic sites
1	43 (79.6 %)	41 (83.7 %)
2 ≤	11 (20.4 %)	8 (16.3)
KRAS status
Mutant	3 (5.6 %)	5 (10.2 %)
Wild	51 (94.4 %)	44 (89.8 %)